Effectiveness and cost of bisphosphonate therapy in tumor bone disease
- 23 January 2003
- Vol. 97 (S3), 859-865
- https://doi.org/10.1002/cncr.11139
Abstract
SCOPUS: cp.jFLWINinfo:eu-repo/semantics/publisheKeywords
This publication has 25 references indexed in Scilit:
- The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple MyelomaDrugs, 2001
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer, 2000
- A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 1999
- Obstructive SyndromesPublished by Taylor & Francis ,1999
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Mechanisms of bone metastasisCancer, 1997
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987